JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online August 18, 2009, 10.2967/jnumed.109.064287
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ren, G.
Right arrow Articles by Cheng, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ren, G.
Right arrow Articles by Cheng, Z.

A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression

Gang Ren1, Rong Zhang2, Zhe Liu1, Jack M. Webster2, Zheng Miao1, Sanjiv S. Gambhir1, Faisal A. Syud2 and Zhen Cheng1

1 Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, California; and 2 Global Research, General Electric Co., Niskayuna, New York


Figure 1
View larger version (43K):
[in this window]
[in a new window]

 
FIGURE 1.  Three-helix Affibody and 2-helix protein scaffold–based PET probes for HER2 imaging. Black dots and red regions indicate amino acid residues responsible for receptor binding.

 

Figure 2
View larger version (6K):
[in this window]
[in a new window]

 
FIGURE 2.  HPLC radiochromatograms of purified 68Ga-DOTA-MUT-DS (A) and radiolabeled probe after 40 min of incubation with mouse serum (B).

 

Figure 3
View larger version (15K):
[in this window]
[in a new window]

 
FIGURE 3.  Biosensor binding studies of DOTA-MUT-DS.

 

Figure 4
View larger version (10K):
[in this window]
[in a new window]

 
FIGURE 4.  Cell uptake of 68Ga-DOTA-MUT-DS in SKOV3 cells over time at 37°C with or without nonradioactive Affibody molecule ZHER2:477. All results are expressed as mean of triplicate measurement ± SD.

 

Figure 5
View larger version (31K):
[in this window]
[in a new window]

 
FIGURE 5.  Representative decay-corrected coronal (top) and transaxial (bottom) PET images of nude mice bearing SKOV3 tumor on right shoulder at 0.5, 1, and 2 h after tail vein injection of 68Ga-DOTA-MUT-DS: nontreated group (A) and treated group (B) (images were acquired after 24 h of treatment with 17-DMAG; arrows indicate location of tumors). (C) Quantification analysis of tumor uptake before and after 17-DMAG treatment. Data are expressed as mean of 3 mice ± SD.

 

Figure 6
View larger version (41K):
[in this window]
[in a new window]

 
FIGURE 6.  Representative Western blot detection of HER2 expression in tumor tissue samples. SKOV3 tumor homogenates were prepared and 50 µg of protein were detected with rabbit antihuman HER2 monoclonal antibody. L1 = lane 1, nontreated tumor; L2 = lane 2, tumor treated with 17-DMAG.

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.